News & Blog

Can Newly Approved “Tissue Agnostic” Drugs Benefit Pediatric High-grade Glioma Patients?

Recently, the U.S. Food and Drug Administration (FDA) granted accelerated approval* to the drug Rozlytrek (entrectinib, Genentech/Roche**) as a treatment for patients, 12 years or older, whose tumors have a specific genetic defect known as an “NTRK gene fusion.”*** This is now the second drug that the FDA has approved to treat patients with this […]

Gliogene: Confronting the Unknown Through Research

As the saying goes, knowledge is power. But, sometimes, it can also be scary. “Oh, it’s horrible!” says Carrie Davis about her quest, which she shares with her sister Hadley, to help better understand links between inheritable genes and brain tumors. She continues, “Every time I get a headache I think I have a brain […]

Brain Tumor ACTION Month 2019

If you’re reading this, your life’s likely been touched by a brain tumor. You have experienced frank conversations about treatment options, changes to your life, and witnessed the firsthand the challenges that come with this disease. For some in our community, “awareness” is a given and the next question is, “how do we move forward?” […]

Share